Novartis | GenomeWeb

Novartis

The business was acquired by two private investment groups and a management group led by Prometheus Laboratories' former CEO.

Under the deal, Novartis will access patients who have used Perthera's Precision Cancer Analysis service, which facilitates molecular profiling of cancers.

Novartis will retain Genoptix's biopharma business, which will be renamed Navigate BioPharma Services.

Amid concerns about buparlisib's toxicity profile, a study suggests there might be a benefit for a subpopulation of patients with a more targeted PI3K inhibitor.

Thermo Fisher developed the NGS-based multi-marker assay in collaboration with Novartis and Pfizer to match lung cancer patients with targeted drugs.

The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.

The companies discussed their plans to change the one-test, one-drug companion diagnostic paradigm at the Personalized and Precision Medicine conference this week. 

Researchers saw abbreviated overall survival times in estrogen receptor-positive metastatic breast cancer patients with ESR1 mutations in their cell-free DNA.

COTA, which also received funding from HealthScape Advisors, said it aims to reduce the amount of money wasted on unnecessary medical treatment.

The financing round includes new investors Anterra Capital, Heritage Group, Maverick Capital Ventures, and Pontifax AgTech.

Pages

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.